Last updated on July 2018

Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Brief description of study

This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Clinical Study Identifier: NCT01909934

Contact Investigators or Research Sites near you

Start Over

Takeda Study Registration Call Center

Spitalul Clinic Judetean de Urgenta Targu Mures
Targu Mures, Romania
  Connect »